Gordon Gary B.

Director Gordon Gary B. buys 10,000 shares of TLSI at $2.46; stock down -61.9% from 52-week high, cluster of 4 other insider buys in past 14 days.

Director Gordon Gary B. purchased 10,000 shares at $2.46 on 2026-05-15, increasing his holdings to 72.5K shares (+16.0% vs pre-transaction holdings). The purchase occurs as the stock trades at $3.03, down -61.9% from its 52-week high of $7.95 and -34.8% over the past 30 days. His prior buy at TLSI on 2026-02-23 showed a 90d return of -34.6%, and across his cross-ticker track record, his 1 prior buy produced an avg 90d return of -34.6% with a 0.00% win rate, indicating a pattern of unfavorable post-purchase price performance. The filing also shows that 4 other insiders bought within the past 14 days, forming a cluster pattern. Against this backdrop, the company reported quarterly revenue of $8.9M and net income of $1.5M, with annual revenue growth of +53.4%, though full-year results were unprofitable and market cap stands at $186.1M.

Director Gordon Gary B. buys 9,756 shares at $4.10; stock down 20.7% in 90 days amid cluster buy by 4 other insiders

Director Gordon Gary B. established an initial 9,756-share position in TriSalus Life Sciences at $4.10 on 2026-02-23, investing $39,999.60 total. This purchase occurs within a 14-day window in which 4 other insiders also bought shares, forming a coordinated cluster-buy pattern. The company is generating revenue growth of +59.0% year-over-year but remains unprofitable with a full-year net income of $-10,811,000.00 and quarterly net income of $-10,811,000.00. The timing of this buy follows a significant stock decline: the current price of $4.99 is -33.5% from the 52-week high of $7.50 and -20.7% lower than 90 days ago. The convergence of multiple insider purchases alongside deteriorated valuation metrics warrants scrutiny of whether insiders view the depressed price as a buying opportunity relative to underlying fundamentals.